Trials / Withdrawn
WithdrawnNCT00506701
Effect of Tadalafil in Chronic Obstructive Lung Disease Patients Suffering From Secondary Pulmonary Hypertension
Pilot Study to Investigate the Effect of Tadalafil on Secondary Pulmonary Hypertension in Chronic Obstructive Pulmonary Disease
- Status
- Withdrawn
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Herlev Hospital · Academic / Other
- Sex
- All
- Age
- 45 Years – 85 Years
- Healthy volunteers
- Not accepted
Summary
Tadalafil may lower the pulmonary artery pressure in patients with Chronic Obstructive Lung Disease and secondary pulmonary hypertension and thereby improve patients quality of life.
Detailed description
Twenty outpatients with Chronic Obstructive Lung Disease (COPD) and secondary pulmonary hypertension are treated in a cross-over design with Tadalafil or placebo for 4 weeks. Primary effect parameter is 6 min. walking test.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tadalafil | 40 mg tablet |
Timeline
- Start date
- 2008-02-01
- Primary completion
- 2010-02-01
- Completion
- 2010-02-01
- First posted
- 2007-07-25
- Last updated
- 2015-03-18
Locations
1 site across 1 country: Denmark
Source: ClinicalTrials.gov record NCT00506701. Inclusion in this directory is not an endorsement.